tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Psoriasis D011565 47 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Burns D002056 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Proteinuria D011507 30 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Obesity D009765 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Erythema D004890 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Aoyama H et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. 1995 Br. J. Dermatol. pmid:8547017
Gharpure VS et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:8547871
Koch K et al. CP-123,369: a potent, orally active immunosuppressive agent. 1995 Inflamm. Res. pmid:8548388
Lionetti P et al. Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. 1995 Adv. Exp. Med. Biol. pmid:8525974
Ku YM et al. Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. 1995 Am J Health Syst Pharm pmid:8528874
Arreaza G et al. Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. 1995 J. Clin. Endocrinol. Metab. pmid:8530625
Clardy J The chemistry of signal transduction. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7529414
Braun W et al. Three-dimensional structure and actions of immunosuppressants and their immunophilins. 1995 FASEB J. pmid:7529736
Kawai M et al. Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1 biosynthesis induced by cytokines in human fibroblasts. 1995 J. Immunol. pmid:7532665
Venkataraman L et al. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. 1995 J. Exp. Med. pmid:7532676
Zarnt T et al. Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond. 1995 Biochem. J. pmid:7529995
Wang CR et al. T cell receptor-mediated signaling events in CD4+CD8+ thymocytes undergoing thymic selection: requirement of calcineurin activation for thymic positive selection but not negative selection. 1995 J. Exp. Med. pmid:7532685
Wera S et al. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. 1995 FEBS Lett. pmid:7530217
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Fung JJ and Starzl TE FK506 in solid organ transplantation. 1995 Ther Drug Monit pmid:8588226
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Jusko WJ Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. 1995 Ther Drug Monit pmid:8588227
Vargas V et al. Alpha-interferon for acute hepatitis C in liver transplant patients. 1995 Transplant. Proc. pmid:7533374
McMaster P et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. 1995 Ther Drug Monit pmid:8588228
Barkholt LM et al. New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. 1995 Transplant. Proc. pmid:7533375
Jusko WJ et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). 1995 Ther Drug Monit pmid:8588229
Teraoka S et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. 1995 Transplant. Proc. pmid:7533381
Lohse DL et al. Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. 1995 Structure pmid:8590008
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Winkler M et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. 1995 Transplant. Proc. pmid:7533433
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Ochiai T et al. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533435
Scantlebury VP et al. Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 1995 Transplant. Proc. pmid:7533436
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Bundick RV et al. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity. 1995 Clin. Exp. Immunol. pmid:7533681
Hirakata Y et al. Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice. 1995 J. Med. Microbiol. pmid:7533840
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Iwasaki K et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. 1995 Drug Metab. Dispos. pmid:7536652
Tumlin JA et al. Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron. 1995 Am. J. Physiol. pmid:7485542
Furukawa F et al. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. 1995 Arch. Dermatol. Res. pmid:7487142
Miranker A and Karplus M An automated method for dynamic ligand design. 1995 Proteins pmid:8749844
Marumo T et al. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. 1995 Hypertension pmid:7536714
Lapa e Silva JR et al. Modulation of the bronchial inflammation in sensitized guinea-pigs by FK506, nedocromil sodium and dexamethasone. 1995 Eur. Respir. J. pmid:7489798
Nowaczyk M et al. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). 1995 Arch. Immunol. Ther. Exp. (Warsz.) pmid:8744655
Schwaninger M et al. Involvement of the Ca(2+)-dependent phosphatase calcineurin in gene transcription that is stimulated by cAMP through cAMP response elements. 1995 J. Biol. Chem. pmid:7536740
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Min Z and Jones NF Limb transplantation in rats: immunosuppression with FK-506. 1995 J Hand Surg Am pmid:7536766
Petrides AS [Do immunosuppressive agents really impair glucose tolerance in liver transplant patients?]. 1995 Z Gastroenterol pmid:7571761
Lyons WE et al. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. 1995 J. Neurosci. pmid:7536825
Wortis HH et al. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536930
Bang H et al. Activation of Ca2+ signaling in neutrophils by the mast cell-released immunophilin FKBP12. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536932
Yamamoto S et al. Cross-species transplantation of photoreceptors with tacrolimus hydrate (FK506) treatment. 1995 Jpn. J. Ophthalmol. pmid:8926639
Lam E et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. 1995 J. Biol. Chem. pmid:7592869
Kanda T et al. Synergistic effects of tacrolimus and human interferon-alpha A/D in murine viral myocarditis. 1995 J. Pharmacol. Exp. Ther. pmid:7542339
Canzanello VJ et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. 1995 J. Am. Soc. Nephrol. pmid:7542491
Conde M et al. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. 1995 Immunology pmid:7538492
Garrett-Engele P et al. Calcineurin, the Ca2+/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase. 1995 Mol. Cell. Biol. pmid:7542741
Skeen MJ and Ziegler HK Activation of gamma delta T cells for production of IFN-gamma is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12. 1995 J. Immunol. pmid:7538532
Baughman G et al. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. 1995 Mol. Cell. Biol. pmid:7542743
Columbo M et al. Human skin mast cells express functional beta 1 integrins that mediate adhesion to extracellular matrix proteins. 1995 J. Immunol. pmid:7538541
Pearlman DA and Connelly PR Determination of the differential effects of hydrogen bonding and water release on the binding of FK506 to native and Tyr82-->Phe82 FKBP-12 proteins using free energy simulations. 1995 J. Mol. Biol. pmid:7538591
Warty V et al. Tacrolimus analysis: a comparison of different methods and matrices. 1995 Ther Drug Monit pmid:7542809
Freeman DJ et al. Stability of FK 506 in whole blood samples. 1995 Ther Drug Monit pmid:7542810
Dumont FJ et al. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. 1995 Cell. Immunol. pmid:7538911
Theopold U et al. FKBP39, a Drosophila member of a family of proteins that bind the immunosuppressive drug FK506. 1995 Gene pmid:7538962
Zhao Y et al. Calcineurin activation protects T cells from glucocorticoid-induced apoptosis. 1995 J. Immunol. pmid:7539018
Lee MJ et al. Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation. 1995 Immunopharmacol Immunotoxicol pmid:7544367
Sauer P et al. In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretion. 1995 J. Hepatol. pmid:7544368
Chang HY et al. Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin. 1995 Nature pmid:7544441
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Llull R et al. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. 1995 Transplant. Proc. pmid:7544504
Horne SM and Young KD Escherichia coli and other species of the Enterobacteriaceae encode a protein similar to the family of Mip-like FK506-binding proteins. 1995 Arch. Microbiol. pmid:7540828
Teutsch M et al. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin. 1995 Int. Immunol. pmid:7540861
Hoshino H et al. Effects of FK506 on an experimental model of colitis in rats. 1995 Aliment. Pharmacol. Ther. pmid:7544633
Mori A et al. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. 1995 Int. Immunol. pmid:7540862
Firdaous I et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. 1995 Clin. Chem. pmid:7544705
Tashiro H et al. Monitoring for engraftment following rat orthotopic liver transplantation by in vitro amplification of Y-chromosome gene using polymerase chain reaction. 1995 Cell Transplant pmid:7540919
Ingels SC et al. Stability of FK506 (tacrolimus) in whole-blood specimens. 1995 Clin. Chem. pmid:7544707
Hikita N et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. 1995 Curr. Eye Res. pmid:7540967
Cardenas ME et al. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. 1995 EMBO J. pmid:7540976
Madsen KL et al. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. 1995 Gastroenterology pmid:7540994
Yang WM et al. Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity. 1995 J. Biol. Chem. pmid:7541038
Kawamura A and Su MS Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain. 1995 J. Biol. Chem. pmid:7541044
Mueller AR et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? 1995 Clin Transplant pmid:7549057
Nagai H et al. Effect of some immunosuppressors on allergic bronchial inflammation and airway hyperresponsiveness in mice. 1995 Int. Arch. Allergy Immunol. pmid:7549508
Jung-Testas I et al. Cyclosporin A promotes nuclear transfer of a cytoplasmic progesterone receptor mutant. 1995 C. R. Acad. Sci. III, Sci. Vie pmid:7583777
Kissinger CR et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. 1995 Nature pmid:8524402
Lauerma AI Immunomodulation of contact dermatitis. 1995 Curr. Probl. Dermatol. pmid:7587333
Cardenas ME et al. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 1995 Curr. Opin. Nephrol. Hypertens. pmid:8591053
Wera S et al. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. 1995 Endocr. Res. pmid:7588431
Lake KD and Canafax DM Important interactions of drugs with immunosuppressive agents used in transplant recipients. 1995 J. Antimicrob. Chemother. pmid:8601538
Cameron AM et al. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. 1995 Cell pmid:8521476
Stoller G et al. A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. 1995 EMBO J. pmid:7588623
Tamura K FK506: mechanism of immunosuppression and adverse-effects. 1995 J Toxicol Sci pmid:8531246
Farcasanu IC et al. Protein phosphatase 2B of Saccharomyces cerevisiae is required for tolerance to manganese, in blocking the entry of ions into the cells. 1995 Eur. J. Biochem. pmid:7588708
Mugiya S et al. Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. 1995 Thromb. Res. pmid:8533130
Kaplan A et al. The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. 1995 J. Dermatol. Sci. pmid:8534611
Zhu X et al. Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells. 1995 Ann. Hematol. pmid:8534762